Corient Private Wealth LP Makes New $2 Million Investment in Smith & Nephew SNATS, Inc. $SNN

Corient Private Wealth LP purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,871 shares of the medical equipment provider’s stock, valued at approximately $1,999,000.

Other large investors have also recently modified their holdings of the company. Bank of America Corp DE purchased a new position in shares of Smith & Nephew SNATS during the second quarter worth about $97,223,000. Caisse de depot et placement du Quebec purchased a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $64,186,000. Man Group plc purchased a new stake in Smith & Nephew SNATS in the second quarter valued at approximately $1,712,000. Jupiter Topco LLC bought a new stake in Smith & Nephew SNATS during the second quarter valued at approximately $3,147,000. Finally, Hsbc Holdings PLC bought a new stake in Smith & Nephew SNATS during the second quarter valued at approximately $14,592,000. Institutional investors own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Morgan Stanley cut shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Wednesday. Zacks Research cut shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Monday, August 24th. Canaccord Genuity Group cut their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Finally, Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $30.93.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $28.68 on Thursday. The stock’s 50-day moving average is $30.17 and its 200 day moving average is $31.52. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Announces Dividend

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be given a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.